Page 1,208«..1020..1,2071,2081,2091,210..1,2201,230..»

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Demand , Economy effect, Research Discoveries with Industrial Chain By 2027 – Market…

Posted: December 29, 2019 at 12:55 pm

Report Description

A recent market intelligence report that is published by Data Insights Partner onParoxysmal Nocturnal Hemoglobinuria (PNH) marketmakes an offering of in-depth analysis of segments and sub-segments in the regional and international Paroxysmal Nocturnal Hemoglobinuria (PNH) market. The research also emphasizes on the impact of restraints, drivers, and macro indicators on the regional and world Paroxysmal Nocturnal Hemoglobinuria (PNH) market over the short as well as long period of time. A detailed presentation of forecast, trends, and dollar values of international Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market is offered. In accordance with the report, the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market is projected to expand at a CAGR of 10% over the period of forecast.

Market Insight, Drivers, Restraints& Opportunity of the Market:

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare disorder mostly happened in early adulthood. This life threatening disorder can be developed by the improper development of red blood cells, improper function of bone marrow and inappropriate blood clots function. Around 1-1.5 cases per 1 Million is suffered from PNH across worldwide, according to a study published by John Hopkins University. Around 30% of the newly diagnosed PNH cases is related to aplastic anemia and altogether 30% of the PNH cases are being treated with immunosuppressive therapy. However, most common symptoms of this life threatening disorder are weakness, shortness of breadth, headache, thrombosis, fever etc.

Request for Report Sample:https://datainsightspartner.com/request-for-sample?ref=10

The global Paroxysmal Nocturnal Hemoglobinuria (PNH) market is driven by the growing population, growing number of bone marrow related disorders and increasing new cases of Paroxysmal Nocturnal Hemoglobinuria (PNH) across worldwide. In addition, the high diagnosis and treatment rate of Paroxysmal Nocturnal Hemoglobinuria (PNH) are the factors which will drive the growth of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market during the forecast period. On the contrary, expensive treatment cost and less awareness about the Paroxysmal Nocturnal Hemoglobinuria (PNH) in the developing countries would offset the growth of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market in the upcoming period. Increasing research and development expenditure by the key players, Organizational support and the strategic alliance among the prominent companies may bring an opportunity to the global Paroxysmal Nocturnal Hemoglobinuria (PNH) market to propel during the forecast period- for instance, Ultomiris (developed by Alexion Pharma) won the USFDA approval in December 2018.

By geography, North America is anticipated to hold the maximum market share in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market in 2018 followed by the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market in Europe. Predominance of North America and Europe in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market s are due to the prominent diagnosis and treatment rate, strong medical infrastructure and rigorous research and development on biologics. The developing medical infrastuture would likely to drive the Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to propel by the highest CAGR during the forecast period. Less awareness about the Paroxysmal Nocturnal Hemoglobinuria (PNH) in Africa region would hamper the growth of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market in Middle East and Africa region in future.

Segment Covered:

This market intelligence report on the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market encompasses market segments based on treatment type, end-user and geography. On the basis of treatment type, the sub-markets is segmented into medication, stem cell transplant and blood transfusion. By Geography, the global Paroxysmal Nocturnal Hemoglobinuria (PNH) market has been divided into North America (the U.S., Canada), Latin America (Brazil, Mexico, Argentina and other countries),Europe (Germany, France, the U.K., Spain, Italy, Russia, and othercountries), Asia Pacific (India, Japan, China, Australia and New Zealand and other countries), Middle East and Africa (GCC, South Africa, Israel and Other countries).

Profiling of Market Players:

This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as Novartis, Achillion Pharmaceuticals, Inc, Apellis Pharmaceuticals, Alnylam Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Akari Therapeutics, plc, Alexion Pharmaceuticals etc. etc. among others have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as Paroxysmal Nocturnal Hemoglobinuria (PNH) market related investment & spending and developments by major players of the market are tracked in this global report.

Report Highlights:

In-depth analysis of the micro and macro indicators, market trends, and forecasts of demand is offered by this business intelligence report. Furthermore, the report offers a vivid picture of the factors that are steering and restraining the growth of this market across all geographical segments. In addition to that, IGR-Growth Matrix analysis is also provided in the report so as to share insight of the investment areas that new or existing market players can take into consideration. Various analytical tools such as DRO analysis, Porters five forces analysis has been used in this report to present a clear picture of the market. The study focuses on the present market trends and provides market forecast from the year 2017-2027. Emerging trends that would shape the market demand in the years to come have been highlighted in this report. A competitive analysis in each of the geographical segments gives an insight into market share of the global players.

Request for Report Analysis:https://datainsightspartner.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-treatment-market/10

Salient Features:

This study offers comprehensive yet detailed analysis of the Paroxysmal Nocturnal Hemoglobinuria (PNH) market, size of the market (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the period of forecast: 2019 2027, taking into account 2017 as the base year

It explains upcoming revenue opportunities across various market segments and attractive matrix of investment proposition for the said market

This market intelligence report also offers pivotal insights about various market opportunities, restraints, drivers, launch of new products, competitive market strategies of leading market players, emerging market trends, and regional outlook

Profiling of key market players in the world Paroxysmal Nocturnal Hemoglobinuria (PNH) market is done by taking into account various parameters such as company strategies, distribution strategies, product portfolio, financial performance, key developments, geographical presence, and company overview

Leading market players covered this report comprise names such as. Novartis, Achillion Pharmaceuticals, Inc, Apellis Pharmaceuticals, Alnylam Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Akari Therapeutics, plc, Alexion Pharmaceuticals

The data of this report would allow management authorities and marketers of companies alike to take informed decision when it comes to launch of products, government initiatives, marketing tactics and expansion, and technical up gradation

The world market for Paroxysmal Nocturnal Hemoglobinuria (PNH) market caters to the needs of various stakeholders pertaining to this industry, namely suppliers, manufacturers, investors, and distributors for Paroxysmal Nocturnal Hemoglobinuria (PNH) market. The research also caters to the rising needs of consulting and research firms, financial analysts, and new market entrants

Research methodologies that have been adopted for the purpose of this study have been clearly elaborated so as to facilitate better understanding of the reports

Reports have been made based on the guidelines as mandated by General Data Protection Regulation

Ample number of examples and case studies have been taken into consideration before coming to a conclusion

Reasons to buy:

vIdentify opportunities and plan strategies by having a strong understanding of the investment opportunities in the Paroxysmal Nocturnal Hemoglobinuria (PNH) market

vIdentification of key factors driving investment opportunities in the Paroxysmal Nocturnal Hemoglobinuria (PNH) market

vFacilitate decision-making based on strong historic and forecast data

vPosition yourself to gain the maximum advantage of the industrys growth potential

vDevelop strategies based on the latest regulatory events

vIdentify key partners and business development avenues

vRespond to your competitors business structure, strategy and prospects

This post was originally published on Market Research Sheets

See the original post:
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Demand , Economy effect, Research Discoveries with Industrial Chain By 2027 - Market...

Posted in New Mexico Stem Cells | Comments Off on Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Demand , Economy effect, Research Discoveries with Industrial Chain By 2027 – Market…

Top Emerging Technologies of the Year – Technowize

Posted: December 29, 2019 at 12:54 pm

Welcome to the 21st century. We might not be able to fly on smart hoverboards yet, but brilliant tech luminaries of our time have brought plenty of wishful devices and tech to our everyday life. It has become increasingly difficult to get a handle on with the pace at which the tech industry moves, but that doesnt mean we lose track of any phenomenal progress that will change our lives for the better. Here are the ten breakthrough technologies of 2019 that will likely be a part of our daily lives in the years to come.

A list of 10 emerging technologies of the year would be incomplete without NASA. When it comes to space, theres a fundamental problem that comes in our way to conquer it. Its big. Even traveling at the speed of light would take us years to reach our nearest neighboring star.

NASA engineer David Burns has developed a conceptual new spaceship thruster he calls the helical engine a concept which could theoretically accelerate to 99 percent the speed of light.

Burns concept has caused quite a buzz New Scientist says it may violate the laws of physics. It utilizes Einsteins theory of special relativity, which states that objects gain mass as they approach the speed of light. The conceptual spaceship could cause forward motion without traditional propellants.

But, theres a long way to go from here. The helical engine is 200 meters long and would generate as much force as throwing lint in the air. For it to achieve the speed of light, it would need to generate 165 megawatts of energy to produce 1 newton of thrust. This is quite inefficient when youre putting so much input for just a tiny bit of output. But, in the vacuum of space, this might just work.

"The engine itself would be able to get to 99 per cent the speed of light if you had enough time and power,"Burns toldNew Scientist.

Humans have been toying with the idea of an invisibility cloak since early civilization. From Athenas Cap of Invisibility to Harry Potters Invisibility Cloak, the notion of making oneself invisible to destroy enemies has always tickled our fancy.

Hyperstealth, a Canadian camouflage design company has patented a new invisible material, called Quantum Stealth, which easily disguises soldiers, or even its tanks, ships, or aircraft. This invisible material is as thin as paper, inexpensive, and requires no source of power. Its not exactly an invisibility cloak but it does a pretty good job of concealing military equipment.

The material uses an approach called a lenticular lens. This material can bend light in such a way that that only things which are very close or quite far off can be seen. Thus, any object or person placed behind this thin material will not appear to the naked eye. Thus light can be in the visible spectrum, or it can be infrared, ultraviolet, or shortwave infrared light, making the material a broadband invisibility cloak.

For years, researchers have been working to grow simplified versions of human organs, also known as lab-grown organoids, which could be used to model disease or test out new pharmaceuticals.

Now, a team of Japanese neuroscientists has grown lumps of human brain in a lab. These cells were grown from cultured pluripotent stem cells - cells that have the ability to undergo self-renewal. After growing lumps of cells, the researchers separated them and placed them individually into a petri dish, where they developed their own neural networks. In another study at Harvard, researchers showed that neural networks in the brain organoids were sparked with activity and responded when light was shone on them. In one study, Fred Gage and his colleagues at the Salk Institute in San Diego transplanted human brain organoids into mouse brains and found that they connected up to the bodys blood supply and developed fresh connections.

Brain organoids are a landmark medical advancement as they allow us to better study neurological conditions. This breakthrough, however, has opened up a hot debate on a new ethical dimension of research. Are these brains sentient? If they are, then it means they feel pain and other sensations.

For the first time, neuroscientists have crossed the Rubicon of conscious existence by growing mini-brain in the lab. Some have even been successful in transplanting the brain tissue into animals.

At the worlds largest annual meeting of neuroscientists on October 21, 2019, researchers warned that neuroscientists working on brain organoids are dangerously close to crossing the ethical line. Some worry that researchers may have already done so by growing a brain in the lab.

If theres even a possibility of the organoid being sentient, we could be crossing that line, said Elan Ohayon, the director of the GreenNeuroscienceLaboratory in San Diego, California. We dont want people doing research where there is potential for something to suffer.

Early organoids were used by researchers to study what happens to the brain when it exposed to fatal diseases, like the Zika virus which causes malformations.

Marc Stieglers 1989 short story The Gentle Seduction maintains the idea of a technological Singularity in a rate-of-change sense, with one of the characters superimposing the idea as a time in the future. It'll occur when the rate of change of technology is very great - so great that the effort to keep up with the change will overwhelm us. The heroine of the story lives in a timeline where a majority of mankind is more willing to swallow a pill to restore ones youthful state or take a pill to boost ones mental acuity. An unimaginative, outdoorsy woman, who is hopelessly petrified of technology, she is forced to live a technologically-impaired, forsaken life she doesnt want. One day, the woman ends up taking a new pill robot and transmutes from a techno-neophyte to an organic intelligence. The woman stops aging as the centuries go by, she no longer needs her physical body and can choose to leave it behind and explore the universe as a type of pure mental-energy state.

The reality now seems pretty close to this piece of fiction from 1989. Guillermo Tearney, a pathologist and engineer at Massachusetts General Hospital (MGH) in Boston, is developing small ingestible pills that can be used to inspect the gut for signs of environmental enteric dysfunction (EED) and even obtain tissue biopsies. Studying gut illnesses of young children often requires anesthetizing them and inserting a tube called an endoscope down the throat. Its uncomfortable, expensive and not to mention, impractical in poorer parts of the world where gut illnesses are prevalent.

EED is one of the most expensive illnesses to treat. Its widespread in poor countries and is one of the reasons why children and adults there are malnourished, and never reach a normal body proportion. While we dont exactly know what causes EED and how it could be treated, this pill would make screening easier for medical workers.

The ingestible pill may not promise ever-lasting youth but it has come pretty close to extending ones life in poorer countries. At MGH its being used for practical screening for Barretts esophagus, a precursor of esophageal cancer. Its also being tested on adolescents and infants in Pakistan, where EED is prevalent.

What good are robots if they cant take care of themselves in the physical world? Todays robots can hardly move an object half a meter, let alone replace humans on the assembly line. Weve programmed robots to pick an object but it cant yet figure out how to grasp any object just by looking at it, regardless of its size.

OpenAIs Dactyl is different. Its edge comes from reinforcement learning using which the robot learns how to grasp and turn the block in a simulated environment before it even tries it out for real in the physical environment.

OpenAIs technology is open-source which would make the latest findings evenly and widely distributed, rather than in the hands of a few working closely on Dactyl.

The Intergovernmental Panel on Climate Change (IPCC) asserts that limiting global warming to 1.5C could avert the most cataclysmic effects of climate change. To prevent a dangerous rise in temperatures, the UNs climate panel concludes, the world will need to remove as much as 1 trillion tons of carbon dioxide from the atmosphere this century.

In Switzerland, a giant machine is at bay sucking carbon dioxide directly from the air. The plant can easily capture about 900 tons of CO2 annually or approximate level released from 200 cars.

The Climeworks AG facility near Zurich sits on top of a waste heat recovery facility that powers the process. Fans push air through a filter system that collects carbon dioxide. When the filter is saturated, carbon dioxide is separated at temperatures above 100 degrees Celsius.

Global Thermostat of New York, captures carbon dioxide and hydrogen to produce methane. It built its first commercial plant in Alabama in 2018. So will Carbon Engineering, a Canadian startup co-founded by Harvard climate scientist David Keith in 2009, plans to produce synthetic fuels using the captured carbon dioxide as a key ingredient.

With enough economic data from these plants, we can make accurate calculations for other larger projects to remove carbon dioxide from the atmosphere.

At 24, Thomas Larsson thought he was in the best shape he could be. But his heart rate on the Fitbit tracker told a different story: it was 142 beats per minute (bpm), way above the normal resting rate of 60 bpm.

Todays fitness trackers come with a single sensor, whereas one equipped with ECG has twelve. ECG-enabled smart-watches have made it easier to get precise measurements of heart rate. Todays fitness trackers can quickly detect abnormalities before they cause a stroke or heart attack saving you a visit to the emergency room.

An Apple Watch-compatible tracker from AliveCor can easily detect atrial fibrillation, stroke, and a frequent cause of blood clots. Last year, Apple released its own FDA-approved ECG feature embedded on the Apple Watch itself. Popular health-device maker Withings also plans to roll out an affordable ECG-equipped watch. Todays wearables come with a single sensor, whereas a real ECG has twelve.

Googles Sycamore Quantum Computer has achieved Quantum Supremacy. Meaning, it can perform a calculation way faster than a regular binary computer.

Sycamore completed a random number generation-related calculation in 200 seconds in contrast, the worlds most powerful supercomputer would take 10,000 years to calculate.

Google CEO Sun Pichai has compared this feat to when Wright brothers took off their first plane ride in 1903.

The megacorps biggest rival IBM isnt quite happy with this achievement. IBM argues Googles experimental quantum computer didnt account for plentiful disk storage and other optimization methods. And so, Googles experiment is an excellent demonstration of the progress in superconducting-based quantum computing, IBM researchers wrote, but it shouldnt be viewed as proof that quantum computers are supreme over classical computers.

The head of the Pentagon Joint Artificial Intelligence Center recently declared that deepfake technology poses a grave danger to our national security. So, what is deepfake?

Deepfake is AI-based top emerging technology used to produce or alter video footage so it presents something that never occurred in the first place. Currently, deepfake technology is being misused to edit the faces of celebrities onto people in pornographic videos. This certainly paints a troubling picture where national security is compromised due to AI-generated fake clips.

We saw strong indications of how this could play out in the 2016 election, and we have every expectation that if left unchecked it will happen to us again, Shanahan said at the panel, per C4ISRNET. As a department, at least speaking for the Defense Department, were saying its a national security problem as well. We have to invest a lot in it. A lot of commercial companies are doing these every day. The level of sophistication seems to be exponential.

Its also unfair to assume that this technology will only bring out the worst of humanity. Samsungs AI lab recently made Mona Lisa smile and created a living portrait of Marilyn Monroe, Salvador Dali, and others to create hyper-realistic videos out of a single image.

AI Assistants were supposed to make our lives smarter but theyre found to be lacking the smarts. Alexa, Siri, Cortana, and many others still lack the ability to understand natural language.

OpenAI, a nonprofit, San Francisco-based AI research company backed by Elon Musk, Reid Hoffman, and Peter Thiel, unveiled a neural network called GPT-2, which generates coherent paragraphs of text one word at a time. Googles BERT can predict missing and does a job as well as humans at filling in gaps.

Recent advancements, coupled with better speech synthesis, are allowing us to move from giving AI Assistants like Alexa simple commands to having proper conversations with them. In a few years, Alexa and Siri would deal with daily tasks such as taking meeting minutes, shopping online, or finding information.

Googles Duplex is already there. It can pick up your calls to screen for telemarketers and spammers. The Google Assistant can also make calls for you to make salon appointments or schedule restaurant reservations. AliMe in China can coordinate package deliveries over the phone and haggle prices of goods over chat.

AI Assistants are getting better at figuring our human needs. All we need now is for them to understand a sentence.

Read the original post:
Top Emerging Technologies of the Year - Technowize

Posted in Massachusetts Stem Cells | Comments Off on Top Emerging Technologies of the Year – Technowize

From cow loos to dog fitbits: 20 ways technology will transform the countryside in 2020 – Countryliving (UK)

Posted: December 28, 2019 at 8:43 pm

Rural communities often take solace in the continuity associated with country life. Cities are the place for change, while our countryside is to be treasured for its slower pace. This can make the prospect of new ways of working a daunting one. But not all change is negative some technology increases productivity in farming, some benefits the environment.

Some things do need to change. The National Farmers Union (NFU) has pledged that the industry will reduce greenhouse emissions to zero by 2040, which means farmers are having to come up with eco-friendly ways to meet growing demand.

People often think of agriculture as conservative and slow to adapt, but it has always been about experimentation and trying new things, says Dr Helen Ferrier, chief science and regulatory affairs adviser at the NFU. Technology has a history of making life easier, replacing some jobs and creating new ones, adds Farmers Guardian editor Ben Briggs.

If new technologies help to make agriculture more profitable, they should be welcomed. So, let us introduce 20 innovations that could be coming to a field near you

We all want animals to live stress-free, but how do you ask a pig how its feeling? Scientists at Bristol Robotics Laboratory are using 3D scanners to find out. The machines use artificial intelligence to identify emotions on the animals faces. Farmers could eventually use similar technology to check that their pigs arent in pain or distress, thereby improving animal welfare.

Ammonia and nitrogen pollution harms more than 60% of UK land by acidifying soil and fresh water, and destroying plants. Unfortunately, cows and their bodily functions are partly to blame. But Dutch designer Henk Hanskamp might have the answer: a cow loo. Cows will pay a visit voluntarily (their daily feed given nearby as encouragement), toxins will then be removed from the waste, with the remainder used as fertiliser. The machine could be on sale in the Netherlands in 2020, before it is exported abroad.

Soon, everything and everyone in National Parks could be connected to the internet. Rubbish bins will send alerts to rangers when theyre full, so that they only have to be checked when they need emptying, reducing emissions, while sensors in footpaths will call out rangers to deal with fallen trees and flooding. Signposts at the end of a route will also be sending messages to your oven to have supper ready for when you arrive home well, we can dream, cant we?

Suffolk Punch horses, Britains oldest native breed, once happily ploughed our fields, but now they are dying out, with only about 70 breeding females left. What to do? Equine reproduction specialists Stallion AI Services has found a way to determine the gender of semen so that it can impregnate a filly with a female foal. More breeding females mean more horses in years to come

The ethics of egg-farming can make for uncomfortable reading: farmers require female chickens, as they lay the eggs, leaving the difficult question about what to do with the males. All chicks in Britain are incubated to full term, but German company Seleggt has found a way to determine the sex of a chick before it is born by testing a fluid sample from the egg. Males can then be used in animal feed before they hatch. Seleggt eggs are already sold in Germany and the company hopes to expand across Europe soon.

Meet Tom, Dick and Harry, three autonomous planters that are currently being tested in Hampshire by Waitrose & Partners; Harry plants, Tom places soil on top and Dick zaps weeds with lasers. Being smaller and lighter than tractors, these four-wheeled machines reduce compaction of the soil, improving yields. Theyre also pretty good workers. Small Robot Company CEO Ben Scott-Robinson says, People get tired, but robots dont nor do they get distracted. Robots would support rather than replace farmers, he says, adding that the technology needs further trials.

Almost half the dogs in the UK are overweight, according to vet charity PDSA. The solution? A canine activity tracker attached to your pets collar, monitoring his or her movements and how many calories they are burning. PitPat can tell you whether your dog has been playing, running or walking (39, pitpat.com), while FitBark (65, fitbark.com/store-uk) can also track your dogs sleep restless nights could indicate health problems.

A third of our wild bees and hoverflies are in decline, according to a 2019 study by the Centre for Ecology and Hydrology, but help is on the way in the form of tiny bee-like drones that fly between plants and cross-pollinate them. Created by Harvard University, the solar-powered RoboBee X-Wing can flap its two sets of wings at a rate of 170 beats per second. Growers could use similar drones in greenhouses within five to 10 years.

Farms floating in harbours could make food more sustainable by reducing how far produce travels to consumers while also increasing the land available for agriculture. In Rotterdam, 32 Meuse-Rhine-Issel cows are helping to test this very notion, living on a 30m x 30m, three-storey pontoon, in a project by Dutch property company Beladon. The team is looking to expand into China and one day it could happen here

Almost a third of Britons believe well all be happily chomping away at insects by 2029, according to the Agricultural Biotechnology Council. Insects are great sources of protein, while farming them requires little space and water, and releases fewer greenhouse gases than conventional animal farms. Want a taster? Sainsburys already sells snack-sized packs of grasshoppers, crickets, buffalo worms and mealworms, produced by Eat Grub in the Netherlands (from 4.29 for 20g, also from eatgrub.co.uk), while Selfridges stocks chocolate-chip cricket cookies (5.99, in store only), produced by Bug Farm Foods in St Davids, Wales.

In New Zealand, drones are increasingly taking on sheepdog duties and farmers are now trying them over here. Mark Rutter, of Harper Adams University in Shropshire, thinks its more ethical: sheep happily follow drones, as they already lead them to food, whereas they only obey dogs because they see them as predators. Drones can also cover a fair bit of ground (about four miles), dont mind hilly terrain and wont leave muddy paw prints on the carpet. A basic model such as the DJI Mavic Pro 2 can handle winds of up to 24mph and costs roughly 1,300. Drones that work in the rain cost nearer 6,000. Farmers dont need a licence, but they should be aware of the risks, especially to birds. They also dont like to be scratched behind the ears

Sometimes it just isnt possible to cross the country to see wildlife, but now it can come to you. Webcams run by The Wildlife Trusts follow grey seals in Cumbria and puffins in Alderney, allowing you to watch them from your phone or computer (wildlifetrusts.org/webcams). Most activity takes place from the spring, but theres plenty of grass-munching year-round at The Donkey Sanctuary in Sidmouth, Devon (thedonkeysanctuary.org.uk/webcams).

Wondering where your food really comes from? Started by two farmers, new app Happerley allows you to find out where food is produced by scanning the QR code on the packaging. About 250 food and drink producers have signed up, including Simon Weaver Organic in the Cotswolds, Hayes Fruit Farm in Gloucestershire and Grass Fed Meats, which operates across the UK. Happerley is free and available on the App Store and Google Play.

New energy sources are vital as we move away from fossil fuels and grass could be a solution. In Lincolnshire, the local council, the Environment Agency and The Wildlife Trusts have been turning roadside cuttings into electricity. A tractor-like machine sucks up the grass and takes it to an anaerobic digestor, which converts it into energy. It is estimated that Lincolnshires 5,500 miles of rural roads could generate a years worth of electricity for 4,500 homes.

In the US, you can already buy burgers and meatballs made of meat grown in labs from animal stem cells, while in Europe, Netherlands-based Mosa Meat predicts its product could be in supermarkets within four years. Still hesitant? Conventional farming will continue to have a place. The NFUs Dr Helen Ferrier says lab-grown meat will simply start a useful conversation about what people want to eat.

Most of the prawns we eat in the UK come from farms in the Far East and Central America, but the future could be different. Great British Prawns, the worlds first sustainable, clean-water, land-based prawn farm, in Balfron, Stirlingshire, began harvesting a million prawns last summer, selling them to nearby chefs. The company is now planning more farms to supply restaurants across the UK.

Sompong Sriphet / EyeEmGetty Images

Good news for professional gardeners and groundsmen RootWave has patented a wand-like device that zaps weeds with an electric pulse, killing them without chemicals and allowing them to decompose in the soil. The zapper is already available to commercial growers, and CEO Andrew Diprose hopes a version will eventually be available for hobby gardeners.

In 2019, there was a shortfall of 6,000 soft-fruit pickers in the UK. More robots to the rescue. Hall Hunger Farm, near Chichester, West Sussex, is trying out machines on wheels with 3D cameras and four sets of grippers. Designed by the University of Plymouths Fieldworks Robotics lab, the machines (below) are expected to go into production within a year.

Fruit and vegetables could be grown in some of the UKs 150,000 abandoned coal mine shafts, predicts Professor Saffa Riffat, president of the World Society of Sustainable Energy Technology. This would reduce the environmental costs of transporting food from far away, as well as cutting the need for pesticides. Salads grown in tunnels in south-west London are already sold through Ocado (Growing Underground, 2.59 for 70g, ocado.com).

Want to cut down on garden plastic? Bristol-based start-up Candide Labels has devised an app that identifies plants and creates virtual labels you store on your phone. Simply hold your camera-phone up to a plant and tap the screen, enabling it to identify the plant and tag it. Candide is free and available on the App Store and Google Play.

This feature is from Country Living magazine. Subscribe here.

Like this article? Sign up to our newsletter to get more articles like this delivered straight to your inbox.

SIGN UP

Read the original here:
From cow loos to dog fitbits: 20 ways technology will transform the countryside in 2020 - Countryliving (UK)

Posted in New Hampshire Stem Cells | Comments Off on From cow loos to dog fitbits: 20 ways technology will transform the countryside in 2020 – Countryliving (UK)

Hepatitis C, cell therapy among breakthroughs in decade of progress – The Columbian

Posted: December 28, 2019 at 8:42 pm

Luckily, more options are on their way. Some drugmakers are focused on different types of blood cancers. Others hope to mitigate side effects or create treatments that can be grown from donor cells to reduce expenses and speed up treatment. In the longer run, companies are targeting trickier solid tumors. Scientists wouldnt be looking so far into the future without this decades extraordinary progress.

Researchers have spent years trying to figure out how to replace faulty DNA to cure genetic diseases, potentially with as little as one treatment. Scientific slip-ups and safety issues derailed a wave of initial excitement about these therapies starting in the 1990s; the first two such treatments to be approved in Europe turned out to be commercial flops.

This decade, the technology has come of age. Luxturna, a treatment developed by Spark Therapeutics Inc. for a rare eye disease, became the first gene therapy to get U.S. approval in late 2017. Then in May came the approval of Novartis AGs Zolgensma for a deadly muscle-wasting disease. The drugs have the potential to stave off blindness and death or significant disability with a single dose, and, unsurprisingly, Big Pharma has given them a substantial financial endorsement. Roche Holding AG paid $4.7 billion to acquire Spark this year, while Novartis spent $8.7 billion in 2018 to buy Zolgensma developer Avexis Inc.

Dozens of additional therapies are in development for a variety of other conditions and should hit the market in the next few years. They offer the tantalizing potential not just to cure diseases, but to replace years of wildly expensive alternative treatment. If drugmakers can resist the temptation to squeeze out every ounce of value by doing things like charging $2.1 million for Zolgensma, theres potential for these treatments to save both lives and money.

The above treatments modify DNA; this group uses the bodys messaging system to turn a patients cells into a drug factory or interrupt a harmful process. Two scientists won a Nobel Prize in 2006 for discoveries related to RNA interference (RNAi), one approach to making this type of drug, showing its potential to treat difficult diseases. That prompted an enormous amount of hype and investment, but a series of clinical failures and safety issues led large drugmakers to give up on the approach. Sticking with it into this decade paid off.

Read more:
Hepatitis C, cell therapy among breakthroughs in decade of progress - The Columbian

Posted in Cell Therapy | Comments Off on Hepatitis C, cell therapy among breakthroughs in decade of progress – The Columbian

Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets – Business Wire

Posted: December 28, 2019 at 8:42 pm

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced that it has entered into license agreements with three separate companies, each relating to different parts of Lineages intellectual property portfolio. All three companies have ongoing commercial operations, including with respect to their cell therapy-related assets. The aggregate up-front cash payment from the transactions was greater than one million dollars with additional cash and royalties due upon reaching certain development milestones or product sales.

Lineage is a leading cell therapy company with clinically-validated technology based on one of the largest and most comprehensive patent estates in cell therapy, stated Brian M. Culley, CEO. We believe our IP estate has increased in value in part due to advancements made by us and others in the field of cell therapy. As a result, we have placed a greater emphasis on completing business development transactions which can help fund our operations without having to raise capital at unattractive prices. We have entered into three separate agreements with entities in the cell therapy space for the license, development, manufacture and sale of products based on our broad cell therapy platform and technologies. Each of the agreements are with companies which have already commercialized cell therapy-related assets and are well-positioned to advance our programs. We believe these partnerships help validate the superiority of our well-characterized and NIH-approved human cell lines, which are not genetically manipulated, and provide an external endorsement of our inventions. We intend to provide further updates to our stockholders as we work with our new partners. We also are pursuing external partnership opportunities to support the development of our OpRegen, OPC1 and VAC2 programs, each of which may represent billion-dollar market opportunities in the emerging fields of cell therapy and immuno-oncology.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe, may, will, estimate, continue, anticipate, design, intend, expect, could, plan, potential, predict, seek, should, would, contemplate, project, target, tend to, or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the evaluation of business development opportunities. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineages business and other risks in Lineages filings with the Securities and Exchange Commission (the SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading Risk Factors in Lineages periodic reports with the SEC, including Lineages Annual Report on Form 10-K filed with the SEC on March 14, 2019 and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Read the original:
Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets - Business Wire

Posted in Cell Therapy | Comments Off on Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets – Business Wire

Animal Stem Cell Therapy Market: Challenges and Opportunities Report 2017 2025 – Bulletin Line

Posted: December 28, 2019 at 8:42 pm

The comprehensive report published by Persistence Market Research offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Animal Stem Cell Therapy Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Animal Stem Cell Therapy Market during the forecast period 2017 2025.

As per the findings of the presented study, the Animal Stem Cell Therapy Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Animal Stem Cell Therapy in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/14941

The report segregates the Animal Stem Cell Therapy Market into different segments to provide a detailed understanding of the various aspects of the market. The competitive analysis of the Animal Stem Cell Therapy Market includes valuable insights based on which, market players can formulate impactful growth strategies to enhance their presence in the Animal Stem Cell Therapy Market.

Key findings of the report:

The report aims to eliminate the following doubts related to the Animal Stem Cell Therapy Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/14941

Reasons to buy from PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Link:
Animal Stem Cell Therapy Market: Challenges and Opportunities Report 2017 2025 - Bulletin Line

Posted in Cell Therapy | Comments Off on Animal Stem Cell Therapy Market: Challenges and Opportunities Report 2017 2025 – Bulletin Line

PI3K Inhibitors Increased T-Cell Expansion Ahead of CAR-T Cell Therapy – Cancer Therapy Advisor

Posted: December 28, 2019 at 8:42 pm

Expansion of T cells collected for use with chimeric antigen receptor T-cell (CAR-T) therapy can be significantly increased when phosphoinositide 3-kinase (PI3K) inhibitors are added to the culture, according to data presented recently at the 34th Annual Meeting & Preconference Programs of the Society for Immunotherapy of Cancer, or SITC 2019.1

CAR-T cells are generated from apatients own lymphocytes, which are genetically modified in a lab to express asynthetic antigen receptor that targets them to that patients own cancercells.

In order for CAR-T cells to be given topatients, they must expand in a lab for a period of 1 to 2 weeks, explainedstudy author Edmund K. Waller, MD, PhD, FACP, of Winship Cancer Institute,Atlanta, Georgia. In some patients who have had extensive prior chemotherapyexposure, their T cells do not grow to a satisfactory extent to allow them toreceive CAR-T.

Dr Waller worked with Christopher R.Funk, BS, a medical student at Emory, to define laboratory conditions thatcould enhance the expansion of T cells and generate more effective T cells foruse in CAR-T manufacturing.

Specifically, they explored the effect ofsmall-molecule inhibitors of the PI3 kinase to modify the behavior of T cellsduring laboratory expansion. This line of research was prompted by theclinical observation that patients treated with PI3 kinase inhibitors developedautoimmune disease as a side effect of drug therapy, Dr. Waller said. Wereasoned that PI3 kinase inhibitors might augment T-cell expansion when addedto cells in the laboratory.

The team showed that expansion of T cellscan be increased significantly when PI3K inhibitors idelalisib, a PI3K deltainhibitor, or duvelisib, a dual PI3K delta and gamma inhibitor, were added tothe culture.

In addition, they successfully expanded Tcells from lymphoma patients who were heavily pretreated with prior rounds ofchemotherapy and whose T cells would have ordinarily failed the manufacturingstep in CAR-T, Dr Waller said.

In these patients, PI3K inhibitorsincreased frequencies of CD8 cells and costimulatory molecule-expressing cells.The addition of idelalisib also resulted in a dose-dependent decrease in immunecheckpoint molecules LAG3, Tim-3, and PD-1.

Looking at the T-cell differentiationstate, the PI3K inhibitors increased the frequency of early, memory, andeffector memory cells. Finally, PI3K inhibitors also significantly increasedmitochondrial mass within total CD3 and CD8 subsets.

The end result is that we are able tomanufacture, in a shorter time, more potent T cells from patients who havereceived prior chemotherapy treatment, thus, facilitating CAR-T manufacturing,Dr Waller said.

Go here to read the rest:
PI3K Inhibitors Increased T-Cell Expansion Ahead of CAR-T Cell Therapy - Cancer Therapy Advisor

Posted in Cell Therapy | Comments Off on PI3K Inhibitors Increased T-Cell Expansion Ahead of CAR-T Cell Therapy – Cancer Therapy Advisor

Poorly Oscar still waiting for CAR-T cell therapy as treatment is ‘put on hold’ – Worcester News

Posted: December 28, 2019 at 8:42 pm

A SICK schoolboy will be spending Christmas in Singapore to receive treatment as he continues to fight his battle against leukaemia.

Oscar Saxelby-Lee is still waiting to receive CAR-T cell therapy - which is only available in Singapore as no other treatment options were available on the NHS - to treat his T-cell acute lymphoblastic leukaemia.

The treatment was due to start today (December 24), according to the Hand in Hand for Oscar Facebook page, however it has been forced to be put on hold.

The five-year-old has been given steroids as his blood results have come back high.

Oscars family have also been told there is a high possibility of secondary haemophagocytic lymphohistiocytosis (HLH) reoccurring.

HLH is a rare immune disorder where the body reacts inappropriately to a trigger, usually an infection.

This means Oscars specialised white blood cells (known as T-cells) have become over-activated, causing severe inflammation and damage to tissues such as the liver, spleen and bone marrow.

The original Facebook post reads: We have movement around the bed today. Still spiking temperatures but they are slowly phasing out from being consistent.

We are opening more Christmas cards and his face says it all. Thank you to everyone who has sent a little something over and to his classmates at Pitmaston who each decorated a card.

READ MORE:

Hundreds queue for opening of The Range in Worcester with one customer there at 5.50am

Tom Jones' mum: We want to prevent others feeling this grief

The following post said: Back track..... Cell infusion is on hold.

Steroids have been administered as Oscars blood results and certain markers have come back high.

Theres a high possibility of secondary HLH reoccurring so we must treat first. Never ending.

Oscars parents, Olivia Saxelby and Jamie Lee, pleaded for help to raise 500,000 after being told that, despite a bone marrow transplant, Oscars leukaemia had returned.

The community backed the campaign and raised the huge sum in just over three weeks.

Read more here:
Poorly Oscar still waiting for CAR-T cell therapy as treatment is 'put on hold' - Worcester News

Posted in Cell Therapy | Comments Off on Poorly Oscar still waiting for CAR-T cell therapy as treatment is ‘put on hold’ – Worcester News

Have you tried immunotherapy to treat cancer? Calling All Readers – cleveland.com

Posted: December 28, 2019 at 8:42 pm

CLEVELAND, Ohio Immunotherapy, which boosts a patients immune system to destroy cancer cells, is widely seen as the future of cancer care.

This kind of therapy uses substances made by the body, or in a laboratory, to improve or restore the immune system. It can slow the growth of cancer cells, help the immune system do a better job of destroying tumors and slow the spread of cancer to other parts of the body.

There are several kinds of immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors. In CAR-T, white blood cells called T cells are genetically modified to activate the immune system to recognize and destroy certain cancers.

Immune checkpoint inhibitors are drugs that block proteins made by some immune system cells. When these proteins are blocked, T cells are better able to kill cancer cells.

Cancer vaccines, which are used to prevent and treat cancer, also are a kind of immunotherapy.

Have you or a family member experienced immunotherapy treatment for cancer? Was the treatment effective or ineffective? We want to hear your story.

Please write a short email, no more than 500 words, about your experiences with immunotherapy. Include your full name, age, city and daytime phone number. Your name, age and city will be published with your comment, but your phone number will be kept private.

Comments must be received by Friday, Jan. 10.

Go here to see the original:
Have you tried immunotherapy to treat cancer? Calling All Readers - cleveland.com

Posted in Cell Therapy | Comments Off on Have you tried immunotherapy to treat cancer? Calling All Readers – cleveland.com

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2025 – News Distribute

Posted: December 27, 2019 at 3:46 pm

Data Bridge Market ResearchLorea is a professional writer with expertise in industry research.

She had worked with many corporates prior to joining research

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market,By Applications (Eurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, Cardiovascular Diseases), By Product (Blood Pressure (BP) Monitoring Devices, Pulmonary Pressure Monitoring Devices, Intracranial Pressure (ICP) Monitoring Devices), By End User (Hospitals And Ambulatory Surgical Center), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is expected to reach USD113.04 billion by 2025, from USD 87.59 billion in 2017 growing at a CAGR of 3.7% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2015 & 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

For In depth Information Get Sample Copy of this Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market

In autologous stem-cell transplantation persons own undifferentiated cells or stem cells are collected and transplanted back to the person after intensive therapy. These therapies are performed by means of hematopoietic stem cells, in some of the cases cardiac cells are used to fix the damages caused due to heart attacks. The autologous stem cell and non-stem cell based therapies are used in the treatment of various diseases such as neurodegenerative diseases, cardiovascular diseases, cancer and autoimmune diseases, infectious disease. According to World Health Organization (WHO), cardiovascular disease (CVD) causes more than half of all deaths across the European Region. The disease leads to death or frequently it is caused by AIDS, tuberculosis and malaria combined in Europe. With the prevalence of cancer and diabetes in all age groups globally the need of steam cell based therapies is increasing, according to article published by the US National Library of Medicine National Institutes of Health, it was reported that around 382 million people had diabetes in 2013 and the number is growing at alarming rate which has increased the need to improve treatment and therapies regarding the diseases.

Major Market Drivers and Restraints:

Introduction of novel autologous stem cell based therapies in regenerative medicine

Reduction in transplant associated risks

Prevalence of cancer and diabetes in all age groups

High cost of autologous cellular therapies

Lack of skilled professionals

Browse Detailed TOC, Tables, Figures, Charts and Companies @https://www.databridgemarketresearch.com/toc/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The global autologous stem cell and non-stem cell based therapies market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of autologous stem cell and non-stem cell based therapies market for global, Europe, North America, Asia Pacific and South America.

Some of the major players operating in the global autologous stem cell and non-stem cell based therapies market are Antria (Cro), Bioheart, Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Genesis Biopharma, Georgia Health Sciences University, Neostem, Opexa Therapeutics, Orgenesis, Regenexx, Regeneus, Tengion, Tigenix, Virxsys and many more.

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaseRequest an Analyst Callor can drop down your inquiry.

Demand Side Primary Contributors: Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others

Speak to Author of the report @ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingCorporatesales@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

See the article here:
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2025 - News Distribute

Posted in Georgia Stem Cells | Comments Off on Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2025 – News Distribute

Page 1,208«..1020..1,2071,2081,2091,210..1,2201,230..»